What is IMHA, and why does a cat's own immune system turn against its red blood cells?

Immune mediated hemolytic anemia (IMHA) — also called autoimmune hemolytic anemia (AIHA) — is a disorder in which the cat's immune system produces antibodies that mistakenly tag its own red blood cells for destruction. These antibody-coated red blood cells are removed from circulation by the spleen and liver, or they rupture directly in the bloodstream (intravascular hemolysis). The result is anemia that can develop over days to weeks, or — in the most dangerous form — crash within hours. The bone marrow tries to compensate by churning out new red blood cells at an accelerated rate, but in fulminant cases, the destruction outpaces production so dramatically that the packed cell volume can drop to life-threatening levels within a single day (Garden et al., 2019).

IMHA is classified as primary (idiopathic) when no underlying trigger can be identified, and secondary (associative) when it is linked to an identifiable cause: certain medications, infections such as Mycoplasma haemofelis or feline leukemia virus (FeLV), or neoplasia such as lymphoma. In cats, secondary IMHA appears to be more common than the primary form, which differs from the pattern seen in dogs where idiopathic IMHA predominates. The ACVIM consensus statement on IMHA recommends the terms "non-associative" and "associative" to replace "primary" and "secondary," emphasizing that a thorough search for triggers is mandatory before labeling a case as idiopathic. This distinction matters because treating associative IMHA requires addressing the underlying trigger — antibiotics for Mycoplasma, chemotherapy for lymphoma — in addition to suppressing the immune attack (Garden et al., 2019).

What signs should make an owner suspect their cat has IMHA?

The clinical signs of IMHA reflect both the anemia itself and the body's attempt to compensate for oxygen deprivation. Pale or yellow-tinged (icteric) gums are the most visible clue — the pallor comes from the lack of red blood cells, and the jaundice from the breakdown of hemoglobin into bilirubin. Owners may notice their cat sleeping more than usual, breathing rapidly or with effort, and showing little interest in food. The heart rate increases as the cardiovascular system tries to deliver what little oxygen remains to tissues. A cat that normally greets its owner at the door may suddenly spend all day under the bed (Merck Veterinary Manual, 2024).

In acute, severe hemolysis, the cat may collapse. The urine can turn dark brown or port-wine colored from hemoglobinuria — free hemoglobin spilling into the urine after red blood cells rupture inside blood vessels. This is a hallmark of intravascular hemolysis and signals a crisis. A fever may be present if the hemolysis triggers a systemic inflammatory response. Because these signs can mimic many other diseases — including chronic kidney disease, heart failure, and infectious anemia — IMHA is often not the first diagnosis an owner or even a general practitioner considers. The average time from onset of clinical signs to diagnosis can be days to a week, during which the anemia worsens (Garden et al., 2019).

How does a veterinarian diagnose IMHA, and what tests rule out the mimics?

Diagnosis begins with a packed cell volume (PCV) or hematocrit — a simple test that measures the percentage of blood volume occupied by red blood cells. A cat with IMHA typically has a PCV below 25% (normal is approximately 30–45%), and in severe cases it can drop below 10%. A blood smear examined under the microscope reveals spherocytes — small, dense red blood cells that have lost part of their membrane after partial phagocytosis — and often autoagglutination, where red blood cells clump together on the slide even without anticoagulant. True autoagglutination is highly suggestive of IMHA and can be confirmed in-clinic with a saline dispersion test (Merck Veterinary Manual, 2024).

The direct Coombs test (direct antiglobulin test) detects antibodies or complement proteins bound to the surface of red blood cells and is the confirmatory test for IMHA. However, false negatives can occur — particularly if the cat has already received corticosteroids — and a negative Coombs test does not rule out IMHA if the clinical picture and other findings are consistent. Additional testing — FeLV/FIV serology, Mycoplasma haemofelis PCR, abdominal imaging to screen for neoplasia, and a thorough drug history — is essential to identify or exclude associative triggers. A slide agglutination test performed in-clinic can provide a rapid presumptive diagnosis while awaiting Coombs results, which typically take 3 to 5 days to return from a reference laboratory (Garden et al., 2019).

What does treatment involve, and why is it a marathon, not a sprint?

Immunosuppression is the cornerstone of IMHA treatment. Prednisolone — a glucocorticoid — is the first-line drug, typically started at 2–4 mg/kg/day and tapered very slowly over months as the PCV stabilizes. The goal is to suppress the aberrant immune response while avoiding the serious side effects of long-term steroid use: diabetes mellitus, muscle wasting, skin fragility, and increased susceptibility to infection. Cats generally tolerate glucocorticoids better than dogs, but monitoring for hyperglycemia and urinary tract infections is still essential. The taper itself is an art: reduce too fast and the cat relapses; reduce too slowly and the cat suffers unnecessary side effects (Merck Veterinary Manual, 2024).

For cats that do not respond to prednisolone alone, or for those in whom the steroid dose cannot be tapered without relapse, a second immunosuppressant is added. Cyclosporine and mycophenolate mofetil are the most commonly used adjunctive agents. Cyclosporine requires therapeutic drug monitoring to ensure adequate blood levels, while mycophenolate is dosed by body weight and generally well-tolerated, though gastrointestinal upset can occur. In fulminant cases with a PCV below 10–12%, blood transfusion is life-saving, providing oxygen-carrying capacity while immunosuppressive drugs take effect. Transfused red blood cells will also be targeted by the same antibodies, so transfusion buys time — it does not treat the disease. Some cats require multiple transfusions during the first week of treatment (Garden et al., 2019).

Antithrombotic therapy is an increasingly recognized component of IMHA management. Dogs with IMHA have a well-documented risk of thromboembolic disease, and while data in cats are more limited, the hypercoagulable state associated with severe systemic inflammation likely applies across species. Low-dose aspirin or clopidogrel may be prescribed, particularly in cats with very low PCVs or evidence of intravascular hemolysis. The risk of thromboembolism is highest in the first two weeks after diagnosis, which is also the period of highest mortality (Merck Veterinary Manual, 2024).

What is the prognosis — and what does recovery actually look like?

IMHA carries a guarded prognosis. Reported mortality rates range from approximately 20% to 75%, with most deaths occurring in the first two weeks after diagnosis due to severe anemia, thromboembolism, or complications of immunosuppression (Merck Veterinary Manual, 2024). Cats that survive the initial crisis and respond to immunosuppressive therapy can achieve remission, but relapses are common — particularly during attempted drug tapers — and some cats require lifelong low-dose immunosuppression. The financial cost of treating IMHA is substantial: initial hospitalization with transfusions and diagnostics can range from $3,000 to $8,000, with ongoing medication and monitoring costs of $100 to $300 per month.

Recovery is measured in months, not days. The PCV rises slowly, and owners should expect frequent recheck visits — initially weekly, then biweekly, then monthly — to monitor the PCV and adjust medications. A cat that has been in stable remission for 6 to 12 months on a minimal drug dose has a reasonable long-term outlook, but the owner must remain vigilant for signs of relapse: returning pallor, lethargy, or jaundice. The ACVIM consensus statement emphasizes that owner education about the chronic nature of IMHA and the importance of never abruptly stopping immunosuppressive drugs is critical to successful long-term management (Garden et al., 2019).

What symptoms mean this cat needs emergency care tonight?

A cat with known or suspected IMHA who collapses, cannot rise, or is breathing with an open mouth needs immediate emergency care. Pale or white gums that were previously pink, dark brown or red urine, or sudden onset of respiratory distress are all red flags for acute hemolytic crisis. Any cat on immunosuppressive therapy who develops a fever, vomiting, or diarrhea should be evaluated urgently, as immunosuppression increases the risk of severe infections that can become systemic rapidly. If the cat stops eating for more than 24 hours or shows signs of jaundice (yellow gums, skin, or whites of the eyes) that were not present before, do not wait — go to the emergency veterinarian (Merck Veterinary Manual, 2024).

Bottom line

IMHA is one of the most serious hematologic emergencies in cats, but it is not uniformly fatal. Early recognition — pale gums, lethargy, dark urine — and rapid diagnostic workup are the difference between a cat that survives and one that does not. Treatment requires months of immunosuppression, frequent monitoring, and an owner willing to stay the course. With aggressive initial management and careful long-term follow-up, many cats achieve durable remission and return to a good quality of life.

References

Garden, O. A., Kidd, L., Mexas, A. M., et al. (2019). ACVIM consensus statement on the diagnosis of immune-mediated hemolytic anemia in dogs and cats. Journal of Veterinary Internal Medicine, 33(2), 313–334.

Merck Veterinary Manual. (2024). Immune-mediated hemolytic anemia. Merck & Co., Inc. https://www.merckvetmanual.com/circulatory-system/anemia/immune-mediated-hemolytic-anemia